Introduction

De Sanctis-Cacchione syndrome (DSC) is one of the rarest and most severe forms of xeroderma pigmentosum (XP). People with DSC are extremely sensitive to sunlight and may also experience developmental delays, seizures and short stature. Many families face long journeys before reaching a diagnosis, because the syndrome is uncommon.

Genetic testing is crucial in confirming DSC. By identifying the exact gene variant that causes XP in a patient, families gain clarity, doctors can design more specific plans, and relatives can understand their own risks. This article explains what DSC is, what XP variants are, the process of confirmatory genetic testing, and how results can guide care and family planning.

Understanding de sanctis-cacchione syndrome

XP is a rare inherited disorder in which the body cannot properly repair DNA damage caused by UV light. Even small amounts of sun exposure can lead to freckling, skin pigmentation changes, and a dramatically increased risk of skin cancer.^1,2

De Sanctis-Cacchione syndrome represents the most severe end of the XP spectrum.³ In addition to sun sensitivity and skin cancer risk, people with DSC may experience:

• Neurological problems - Seizures, difficulty with movement, hearing loss, or intellectual disability.
• Growth problems - Short stature, delayed milestones.
• Other features -Small head size (microcephaly), vision problems, and developmental delays

Because these features overlap with other conditions, a doctor may suspect DSC based on clinical signs, but genetic testing is usually needed to confirm the diagnosis.

What are XP variants?

XP is not caused by one single mutation. Instead, at least eight different genes can cause XP, each belonging to a complementation group named XPA-XPG and XPV.^4,5 These genes all play roles in repairing UV-induced DNA damage.

• Variants in the XPA gene are especially linked with neurological problems and have been reported most often in patients with DSC⁶
• Other XP genes, such as XPC or XPD, may cause milder forms of XP with mainly skin involvement

Identifying the exact XP variant in a patient helps doctors understand:

• The likely severity of the condition
• Whether neurological problems are expected
• The best approach for surveillance
• Which family members may be at risk

The role of genetic testing

Doctors usually start with clinical suspicion of DSC when a child shows sun sensitivity, freckling, and developmental delays. But clinical symptoms alone cannot provide certainty.

Confirmatory genetic testing identifies the specific XP variant responsible. Modern testing methods include:

• Targeted XP panels - Sequencing all XP-related genes
• Whole exome sequencing (WES) - Studying the protein-coding regions of DNA
• Whole genome sequencing (WGS) - Analysing the entire genetic sequence

These approaches can confirm a diagnosis, rule out similar conditions, and allow carrier testing for family members. For families planning pregnancies, genetic information can be used to consider options such as prenatal testing or in vitro fertilisation with preimplantation genetic testing.⁷

The testing process: what patients can expect

1. Referral - Patients are usually referred to a geneticist or dermatologist familiar with rare genetic conditions
2. Sample collection - A blood sample or cheek swab provides DNA for testing
3. Analysis - The lab sequences DNA and compares it with known XP mutations
4. Results - Findings are reviewed with a genetic counsellor

Results may take weeks to months.

The outcomes can be:

• Positive - A pathogenic XP variant is identified
• Uncertain - A ‘variant of uncertain significance (VUS)’ is found
• Negative - No mutation is found, but this does not rule out DSC completely

Waiting for results can be stressful. Families benefit from ongoing counselling and emotional support throughout the process.⁸

Benefits of confirmatory genetic testing

Confirming the XP variant brings many advantages:

Medical benefits

• Enables more accurate monitoring for skin cancers
• Guides neurological, ophthalmological, and hearing evaluations
• Helps specialists design individualised care plans

Family benefits

• Allows testing of siblings and relatives
• Supports informed family planning decisions

Psychological benefits

• Reduces uncertainty by providing a definitive diagnosis
• Connects families to rare disease networks and research communities

Practical benefits

• Provides eligibility for research studies and registries⁹ 
• Facilitates communication with schools, care providers and social services

Challenges and limitations

Despite its value, genetic testing also has limitations:

• Access - testing may not be available or affordable everywhere
• Inconclusive results - VUS results can leave families in limbo
• Emotional challenges - families may feel guilt or grief after learning the genetic cause
• Uncertainty in prognosis - even with a confirmed mutation, predicting severity can be difficult

This is why genetic counselling is an essential part of the testing process. Counsellors help families understand results, cope with emotions, and make informed decisions.¹⁰

Support after testing

After testing, families typically meet with a genetic counsellor and a multidisciplinary care team. Support often includes:

• Medical specialists - dermatologists for skin care, neurologists for seizures, ophthalmologists for vision, and therapists for development
• Psychological support - counsellors, social workers, or patient support groups
• Patient advocacy groups - such as the Xeroderma Pigmentosum Society and XP Family Support Group, which provide education and peer networks¹¹ 
• Research opportunities - enrollment in rare disease registries and clinical studies, which help families contribute to scientific progress while receiving up-to-date care information

Looking ahead: research and hope

Although there is currently no cure for DSC or XP, research continues to improve understanding and treatment. 

Areas of investigation include:

• Gene therapy approaches to correct DNA repair defects
• Drugs to protect against UV damage and reduce skin cancer risks
• New neurological management strategies to improve quality of life

Families with confirmed genetic diagnoses may be able to participate in clinical trials, which not only provide access to emerging therapies but also contribute to advances for the broader XP community¹² 

Living with de sanctis-cacchione syndrome: practical considerations 

A confirmed genetic diagnosis is only the beginning of the journey for patients and families. Living with DSC requires daily precautions and long-term planning.

Sun protection is the most important day-to-day measure. Families often need to create “sun-safe” environments, including high-SPF sunscreen, protective clothing, wide-brimmed hats, and UV-blocking window films in homes and cars.^1,2 Outdoor play and school activities may need to be carefully scheduled in the early morning or evening.

Regular medical check-ups are essential. Dermatologists check for early signs of skin cancer, while neurologists monitor for seizures or developmental changes. Ophthalmologists watch for eye involvement, which is common in XP.

Education and support can also present challenges. Children may require individualised education plans (IEPs) and classroom adjustments to reduce UV exposure. Teachers and caregivers benefit from clear guidance about the condition, often provided with the help of genetic counsellors or patient advocacy organisations¹¹

Emotional well-being is equally important. Coping with a lifelong rare disease can be stressful. Support groups, counselling, and connecting with other XP families can help reduce feelings of isolation. Families may also find reassurance in knowing that their experiences contribute to broader medical understanding through registries and studies.

By combining strict UV protection, proactive medical care, and emotional support, families can significantly improve quality of life despite the challenges of DSC.

Conclusion

De Sanctis-Cacchione syndrome is a severe and rare form of xeroderma pigmentosum, marked by sun sensitivity, developmental delays, and neurological problems. Because the condition is difficult to diagnose based on symptoms alone, confirmatory genetic testing is vital for patients and families.

Identifying the exact XP variant provides clarity, helps guide medical care, enables family testing, and connects patients with support and research. While challenges remain, genetic confirmation empowers families with knowledge and hope. With ongoing scientific progress, the future holds promise for better treatments and possibly new therapies